BioMarin wins OK in Canada for Morquio A drug Vimizim
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceutical's enzyme replacement treatment (ERT) Vimizim (elosulfase alfa) was approved for use in Canada for Mucopolysaccharidosis Type IVA (MPS IVA), a rare lysosomal storage disorder that causes progressive skeletal dysplasia, including joint deformities and contractures, short stature and spinal cord compression, and reduced pulmonary function, valvular heart disease, hearing loss, cataracts and corneal clouding.